| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,635 |
12,505 |
$2.17M |
| 99215 |
Prolong outpt/office vis |
8,579 |
8,112 |
$1.50M |
| S9083 |
Global fee urgent care centers |
6,851 |
6,385 |
$821K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,520 |
3,193 |
$673K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
22,225 |
16,847 |
$595K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
18,696 |
17,685 |
$371K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,481 |
1,385 |
$203K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12,874 |
12,341 |
$179K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
627 |
594 |
$121K |
| 71046 |
Radiologic examination, chest; 2 views |
1,797 |
1,726 |
$111K |
| 99205 |
Prolong outpt/office vis |
645 |
618 |
$108K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
979 |
908 |
$88K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
525 |
503 |
$83K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,510 |
1,408 |
$81K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,385 |
1,234 |
$76K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,446 |
1,395 |
$67K |
| 73610 |
|
269 |
250 |
$33K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
695 |
672 |
$17K |
| 81001 |
|
1,602 |
1,532 |
$12K |
| 94664 |
|
824 |
744 |
$9K |
| 73140 |
|
147 |
136 |
$7K |
| 73630 |
|
104 |
99 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
154 |
144 |
$4K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
16 |
16 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
12 |
$2K |
| 29130 |
|
31 |
25 |
$2K |
| 74019 |
|
25 |
24 |
$2K |
| 87807 |
|
103 |
94 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,144 |
1,081 |
$1K |
| 87077 |
|
143 |
137 |
$913.29 |
| 87581 |
|
713 |
689 |
$645.93 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
408 |
398 |
$373.46 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
953 |
904 |
$202.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
61 |
43 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
62 |
59 |
$0.00 |
| 87486 |
|
683 |
661 |
$0.00 |
| 85027 |
|
39 |
37 |
$0.00 |
| 87186 |
|
95 |
91 |
$0.00 |
| 85007 |
|
26 |
24 |
$0.00 |
| 29515 |
|
13 |
13 |
$0.00 |